Durata Therapeutics to Present at the 2013 RBC Capital Markets' Global
CHICAGO, Feb. 13, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX)
today announced the company will participate in the RBC Capital Markets'
Global Healthcare Conference scheduled for February 26 and 27, 2013 at The
Plaza Hotel in New York City. Durata's Chief Executive Officer Paul R. Edick
will participate in a fireside chat on Tuesday, February 26, 2013 at 11 a.m.
ET. The fireside chat will be webcast and will be available live and archived
for 30 days at
http://www.veracast.com/webcasts/rbc/healthcare2013/23107333.cfm as well on
the Investor Relations section of the Company's website at
About Durata Therapeutics
Durata Therapeutics is a pharmaceutical company focused on the development and
commercialization of novel therapeutics for patients with infectious diseases
and acute illnesses. Durata has completed its DISCOVER 1 study and enrollment
in its DISCOVER 2 global Phase 3 clinical trials with its lead product
candidate, dalbavancin, for the treatment of patients with acute bacterial
skin and skin structure infections, or ABSSSI.
The Durata Therapeutics, Inc. logo is available at
Any statements in this press release about Durata's future expectations, plans
and prospects constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995, as amended. Actual results
may differ materially from those indicated by such forward-looking statements.
Durata anticipates that subsequent events and developments will cause its
views to change. However, while Durata may elect to update these
forward-looking statements at some point in the future, Durata specifically
disclaims any obligation to do so.
CONTACT: Investor Relations and Public Affairs Contact
Allison Wey - Durata Therapeutics
Vice President, Investor Relations and Public Affairs
(312)219-7017 - firstname.lastname@example.org
Durata Therapeutics, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.